We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pel5.0
Pelargonium Sidoides Research
Mostly mechanism / observationalModerate safety
4 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Pelargonium Sidoides studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2010–2013.
Based on 4 studies · 2 RCTs
Confidence
Low
By outcome
Safety profile
Too few graded studies1 study
Older research base
Newest study from 2013
20102013
1Systematic Reviewn=10 trials; ~746 adults and ~819 children · very large study2013
The liquid preparation of P. sidoides may be effective in relieving symptoms of acute bronchitis in adults and children, but the overall quality of evidence is low to very low.
Timmer A et al. · Cochrane Database Syst Rev (2013)
Liquid EPs 7630 showed effectiveness for acute bronchitis in both adults and children; tablets did not
One study showed significant benefit for sinusitis (RR 0.43, 95% CI 0.30-0.62)
2RCTn=220 children/adolescents · very large study2012
EPs 7630 produced a significantly greater reduction in Bronchitis Severity Score than placebo (4.4 vs 2.9 points; P<0.0001) in children and adolescents.
Kamin W et al. · Pediatr Int (2012)
Significantly greater BSS reduction with EPs 7630 versus placebo (P<0.0001)
Largest improvements in cough and lung auscultation findings
All three EPs 7630 dosage groups showed significantly and clinically relevantly improved patient-reported outcomes versus placebo at day 7 in adults with acute bronchitis.
Matthys H et al. · Wien Med Wochenschr (2010)
All three active dose groups improved patient-reported outcomes versus placebo at day 7
Quality-of-life measures including activity limitation and treatment satisfaction improved
Dose-response relationship observed across active groups
4Review2013
Across trials the Bronchitis Severity Score reliably demonstrated statistically significant differences between EPs 7630 and placebo, with higher responder rates on active treatment.
Matthys H et al. · Curr Med Res Opin (2013)
BSS reliably distinguished active treatment from placebo across studies
EPs 7630 consistently showed higher responder rates than placebo
Methodology paper supporting the primary outcome used in Pelargonium bronchitis trials